Von Pawel-Rammingen, U
Active, not recruiting Atherosclerotic Cardiovascular Disease Drug: Obicetrapib Drug: Placebo Continuation Protocol for Obstructive Sleep Apnea (OSA) The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep
It helps neutralize free radicals, supports liver detoxification, and contributes to brighter, healthier skin
Eligibility for GLP-1 treatment is determined by a licensed clinician and typically involves BMI and medical history criteria
They are intended for superficial application, non medical practice, research or cosmetic use only
Its mechanisms, including weight loss, improved insulin sensitivity, and hepatic lipid regulation, support a possible role in lipid management